Imagine a world where patients are treated for a genetic disorder when they’re only an infant, and they never live with that disorder. Instead, we’ve been able to fix the genetic flaw that they had. Patients who never become patients - they are cured of their diseases before they’ve manifested themselves. That’s the potential of what we’re doing today.

The vision for Brammer Bio is that we are helping to cure, and we can help this industry really transform from decades now of research to now moving ahead into this becoming mainstream.

Just over a decade ago, the human genome was mapped for the first time. This cost over two and a half billion dollars to do, and today, your human genome can be mapped in less than a day, for less than a thousand dollars.

This has created an explosion in our knowledge of genetic diseases. Through that knowledge has emerged a focus on trying to treat those diseases with gene therapy.

The main challenge that Brammer Bio faces today is to be able to grow at the pace needed to support our clients as they move products through and bring them to patients around the world. So to do that, we’re having to build physical capacity, but we’re also having to build organizational capacity.

We needed financing to support our growth, so we turned to Wells Fargo for their expertise.

It’s great to know as we’re working on developing these products that our finances are in good shape, and that we’re working with a collaborator in Wells Fargo who really understands the market that we’re serving. They’re helping us, and helping to cure.

We have the potential to cure diseases. That’s a fantastic future to think about.